Navigation Links
Data Published in Plastic and Reconstructive Surgery Show Cohera Medical's Surgical Adhesive, TissuGlu(R), Prevents Seroma Formation in Animal Abdominoplasty Model
Date:6/19/2008

PITTSBURGH, June 19 /PRNewswire/ -- Cohera Medical Inc. today announced that data published in the July issue of Plastic and Reconstructive Surgery show the company's surgical adhesive, TissuGlu, was effective in preventing the formation of seroma in an animal abdominoplasty model.

Summarized in a paper titled "Lysine-Derived Urethane Surgical Adhesive Prevents Seroma Formation in a Canine Abdominoplasty Model," (Plast. Reconstr. Surg. 2008; Vol. 122, Issue 1: 95-102) the results demonstrated that TissuGlu successfully prevented the formation of seroma in a novel large-animal model designed to evaluate seroma formation. While the control side in all seven animals used in the study demonstrated large, clinically significant seromas, the side treated with TissuGlu showed little or no evidence of fluid accumulation. In addition, histologic analysis of tissue samples from the animals showed no signs of inflammation or foreign body reaction associated with the adhesive.

"I am impressed with the experimental data that demonstrate a clear ability of the adhesive to control seroma formation in this animal model," said J. Peter Rubin, M.D., founder and director of the Life After Weight Loss surgical body contouring program at the University of Pittsburgh and the lead author of the paper. "This adhesive shows strong potential for widespread applications in many surgical specialties."

Surgeons have expressed a strong need for a product that adheres tissue flaps to help prevent the fluid accumulation that occurs between tissue layers after surgery. Surgical adhesives available today fall into two categories: "superglue"-type products that are strong but cannot be used inside the body because they break down into toxic byproducts and "fibrin sealant" products that are biocompatible but create a weak bond and are expensive and difficult to prepare during surgery.

"Seromas have been a major problem for post-surgical patients," said Susan E. Downe
'/>"/>

SOURCE Cohera Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Long-term safety data on Lialda published in leading GI journal
2. Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal
3. New Regulations for Hospice Provision Published by CMS
4. First Comprehensive Reference on Evidence-Based Design Published
5. Premier issue of Environmental Justice just published
6. Safe Options for Cardiac Lead Removal: Study Published in Heart Rhythm Journal
7. Castle Connollys Long Islands Top Doctors Published in Newsday Generates More Than 1.1 Million Views of Top Doctors Profiles in Single Day
8. Northfield Laboratories Inc. Comments on Article and Editorial on Hemoglobin-Based Blood Substitutes to be Published in May 21 JAMA
9. 20th Edition of the Encyclopedia of Social Work Published
10. Clinical guidelines for the manual titration of PAP in OSA patients published in JCSM
11. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2009)...Bertalan Mesko, medical blogger and health 2.0 con...professionals focusing on how the virtual worlds c...pensive and patients are also open to use virtual ...enter a virtual realm and organize medical present...es opportunities for case presentations, e-learnin...
(Date:7/3/2009)..., , FRIDAY, July 3 (HealthDay News) -- Ce... injuries every year in the United States, but tak...rs safe while enjoying the key summer holiday trad...ion, which runs several Georgia-based medical faci..., Obey all local laws regarding fireworks. If you...
(Date:7/3/2009)...t kit called DrugConfirm™ ,is the ideal drug... and accurate instant drug test. Developed by Biot...ek, innovative design and incorporates new Push Bu...y priced compared to the other urine cup products ... San Diego (Vocus) – A n...
(Date:7/3/2009)... a founder of the alternative health movement, is ...w informational Web site devoted to all aspects of... Potomac, MD (Vocus) July 2, 2...native health movement, is now a featured expert o...e devoted to all aspects of joint and muscle condi...
Breaking Medicine News(10 mins):Health News:Put Safety First on the 4th 2Health News:New Urine Drug Test to Detect for 6 Major Drugs, Now Available at Drugstore.com -- 'DrugConfirm' Is a New Revolutionary Urine Drug Test 2Health News:New Urine Drug Test to Detect for 6 Major Drugs, Now Available at Drugstore.com -- 'DrugConfirm' Is a New Revolutionary Urine Drug Test 3Health News:Dr. Julian Whitaker Featured on Searchjointpain.com 2
...oid-beta protein associated with Alzheimers diseas...e transmitted between brain cells , the disruption... researchers at the MassGeneral Institute for Neur...the increased incidence of seizures in Alzheimers ...
...pular in the West. But a UK expert has warned that...eneral term for food, usually vegetables or legume...d to the consistency of a soft paste or thick liqu...ch, where it meant purified or refined.Infants sho...
...ltrasound early in pregnancy, combined with matern...ren born with Down Syndrome . ng of pregnant wom...th maternal blood analysis, has reduced the number...Syndrome by 50%, a scientist will tell the annual ...
...nois, in cooperation with US officials, the US Con...ed 1.5 million "Thomas and Friends" wooden train ...a toxic, lead-based paint. The toys, wooden vehic...s for young children, manufactured between January...
Other Medicine News:Health News:Alzheimers Disease Enzyme may Interfere With Brain Function 2Health News:Pureed Products Unnecessary and Harmful for Babies UK Expert 2Health News:Early Pregnancy Test Reduces Down Syndrome in Children 2Health News:Lead Scare Causes Thomas to Derail 2
(Date:6/30/2009)...ll/ -- Cephalon, Inc. (Nasdaq: CEPH ) today anno...g Application (sNDA) to the U.S. Food and Drug Adm...) (armodafinil) Tablets [C-IV] for the indication ... sleepiness associated with jet lag disorder resul...n acute condition that occurs when a person,s inte...
(Date:6/29/2009)...Newswire/ -- Pioneering therapeutic trials to inv...tion (DBS) in hard-to-treat depression, obsessiv...e are underway at multiple medical centers around ...issue of Mayo Clinic Proceedings . "Deep br... controlling movement disorders," according to the...
(Date:6/28/2009)...rstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: S...e has been achieved in its Research and License Ag...r of the Roche Group, for the generation of cell l... protein production purposes using Sangamo,s propr...FN) technology. Genentech scientists demonstrated ...
(Date:6/26/2009)...irstCall/ -- Sanofi-aventis (EURONEXT: SAN and N...ciated with a retrospective follow-up of four pati...show that no definitive conclusions can be drawn r...ntus(R) (insulin glargine [rDNA] injection) use an...f the study point out. , , Clinical studies, wh...
Breaking Medicine Technology:Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 2Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 3Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 4Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases 2Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases 3Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3Sanofi-aventis Stands Behind the Safety of Lantus(R) 2Sanofi-aventis Stands Behind the Safety of Lantus(R) 3Health Plan of Michigan Ranked Number One Among Medicaid Health Plans in Michigan for Access to Medications for African Americans 19803 1Health Plan of Michigan Ranked Number One Among Medicaid Health Plans in Michigan for Access to Medications for African Americans 19803 2MediVoice Announces Appointment of Edward J Zecchini as Chief Operating Officer 26 Chief Technology Officer 19800 1MediVoice Announces Appointment of Edward J Zecchini as Chief Operating Officer 26 Chief Technology Officer 19800 2Mesa Labs Reports Record Year End Sales and Earnings 19797 1Mesa Labs Reports Record Year End Sales and Earnings 19797 2Mesa Labs Reports Record Year End Sales and Earnings 19797 3Mesa Labs Reports Record Year End Sales and Earnings 19797 4Mesa Labs Reports Record Year End Sales and Earnings 19797 5Mesa Labs Reports Record Year End Sales and Earnings 19797 6Mount Tabor Collaborates with Google Health 19794 1Mount Tabor Collaborates with Google Health 19794 2
...udy Demonstrates 50% Survival in Valortim-Treated ...ch 29, 2007,/PRNewswire-FirstCall/ -- Medarex, Inc...rmAthene, Inc., a privately held,biotechnology com...untermeasures, today announced that Valortim(TM), ...e being developed for the,prevention and treatment...
...ons Reached in Key Lung Compartments, REINACH and ...stCall/ -- Arpida Ltd. today announced promising,r...e radiolabelled,Human Microdose studies included a...dbreaking study is the first ever using Microdosin...lung compartments.,The results showed that AR-709 ...
Other Medicine Technology:Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 8Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 2Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 3Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 4Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 5
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
Medicine Products: